Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
New Insights into Targeted Therapy of Solid Tumors with Polymeric...
share announcement

New Insights into Targeted Therapy of Solid Tumors with Polymeric Nanoparticles

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".

Deadline for manuscript submissions: 10 September 2024 | Viewed by 5544

Special Issue Editors

Dr. Nikita G. Yabbarov

E-Mail Website
Guest Editor
N. M. Emanuel Institute of Biochemical Physics of Russian Academy of Sciences, Moscow 119334, Russia
Interests: nanomaterials; polymeric nanoparticles; anticancer therapy; solid tumor; drug delivery; protein corona; endothelial barrier; blood-brain barrier; enhanced permeability and retention
Prof. Dr. Maxim A. Abakumov

E-Mail Website
Guest Editor
Russian National Research Medical University (RNRMU), The Chair of Medical Nanobiotechnologies, 117997, Ostrovityanova 1, Moscow, Russia
Interests: drug delivery; magnetic nanoparticles; imaging; theranosctics

Special Issue Information

Dear Colleagues,

Cancer is one of the leading causes of death across the globe. Worldwide statistics estimated nearly 20 million new cases and 10 million deaths in 2020. Modern medical treatment has led to the development of state-of-the-art therapeutic and diagnostic techniques and medicines. However, we still experience considerable limitations that impact the general cancer treatment landscape. Highly toxic anticancer treatment demands thorough approaches in drug application. Various polymer nanomaterials and nanoparticles have been extensively studied for drug delivery to solid tumors for over three decades. Today, along with novel mAbs, TK/checkpoint inhibitors, and cell-based treatment, various polymeric formulations have been applied in medicine, including anthracyclines, taxanes, alkaloids, etc., evidencing the applicability of this approach.

We are pleased to invite you to submit original research that describes novel research methods as well as original techniques in the field of the diagnosis and treatment of solid tumors through applying for nanoparticle-based medicines. Research areas may include (but are not limited to) the following: the application of polymeric nanoparticles for drug delivery as a diagnostic and treatment of solid tumors, including lipids, metals, and carbohydrate variations, among others.

 Authors are invited to submit their latest results. Original papers and reviews are welcome.

We look forward to receiving your contributions.

Dr. Nikita G. Yabbarov
Prof. Dr. Maxim A. Abakumov
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanomaterials
  • polymeric nanoparticles
  • anticancer therapy
  • solid tumor
  • drug delivery
  • protein corona
  • endothelial barrier
  • blood-brain barrier
  • enhanced permeability and retention

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

29 pages, 14732 KiB  
Article
Pharmaceutical Approach to Develop Novel Photosensitizer Nanoformulation: An Example of Design and Characterization Rationale of Chlorophyll α Derivative
by Maria B. Sokol, Veronika A. Beganovskaya, Mariia R. Mollaeva, Nikita G. Yabbarov, Margarita V. Chirkina, Dmitry V. Belykh, Olga M. Startseva, Anton E. Egorov, Alexey A. Kostyukov, Vladimir A. Kuzmin, Sergei M. Lomakin, Natalia G. Shilkina, Alexey V. Krivandin, Olga V. Shatalova, Margarita A. Gradova, Maxim A. Abakumov, Aleksey A. Nikitin, Varvara P. Maksimova, Kirill I. Kirsanov and Elena D. Nikolskaya
Pharmaceutics 2024, 16(1), 126; https://doi.org/10.3390/pharmaceutics16010126 - 18 Jan 2024
Viewed by 1030
Abstract
In this study, we described physico-chemical properties of novel nanoformulation of photosensitizer-pyropheophorbide α 17-diethylene glycol ester (XL) (chlorophyll α derivative), revealing insights into antitumor activity and maintaining quality, meeting the pharmaceutical approach of new nanoformulation design. Our formulation, based on poly(lactic-co-glycolic acid) (PLGA) [...] Read more.
In this study, we described physico-chemical properties of novel nanoformulation of photosensitizer-pyropheophorbide α 17-diethylene glycol ester (XL) (chlorophyll α derivative), revealing insights into antitumor activity and maintaining quality, meeting the pharmaceutical approach of new nanoformulation design. Our formulation, based on poly(lactic-co-glycolic acid) (PLGA) nanoparticles, increased XL solubility and selective tumor-targeted accumulation. In our research, we revealed, for the first time, that XL binding to polyvinyl alcohol (PVA) enhances XL photophysical activity, providing the rationale for PVA application as a stabilizer for nanoformulations. Results of FTIR, DSC, and XRD revealed the physical interactions between XL and excipients, including PVA, indicating that the encapsulation maintained XL binding to PVA. The encapsulated XL exhibited higher photophysical activity compared to non-encapsulated substance, which can be attributed to the influence of residual PVA. Gamma-irradiation led to degradation of XL; however, successful sterilization of the samples was achieved through the filtration. Importantly, the encapsulated and sterilized XL retained cytotoxicity against both 2D and 3D tumor cell models, demonstrating the potential of the formulated NP–XL for photodynamic therapy applications, but lacked the ability to reactivate epigenetically silenced genes. These findings provide valuable insights into the design and characterization of PLGA-based nanoparticles for the encapsulation of photosensitizers. Full article
(This article belongs to the Special Issue New Insights into Targeted Therapy of Solid Tumors with Polymeric Nanoparticles)
►▼ Show Figures

Figure 1

Review

Jump to: Research

14 pages, 850 KiB  
Review
Overview of Solid Lipid Nanoparticles in Breast Cancer Therapy
by Kyumin Mo, Ayoung Kim, Soohyun Choe, Miyoung Shin and Hyunho Yoon
Pharmaceutics 2023, 15(8), 2065; https://doi.org/10.3390/pharmaceutics15082065 - 31 Jul 2023
Cited by 3 | Viewed by 1741
Abstract
Lipid nanoparticles (LNPs), composed of ionized lipids, helper lipids, and cholesterol, provide general therapeutic effects by facilitating intracellular transport and avoiding endosomal compartments. LNP-based drug delivery has great potential for the development of novel gene therapies and effective vaccines. Solid lipid nanoparticles (SLNs) [...] Read more.
Lipid nanoparticles (LNPs), composed of ionized lipids, helper lipids, and cholesterol, provide general therapeutic effects by facilitating intracellular transport and avoiding endosomal compartments. LNP-based drug delivery has great potential for the development of novel gene therapies and effective vaccines. Solid lipid nanoparticles (SLNs) are derived from physiologically acceptable lipid components and remain robust at body temperature, thereby providing high structural stability and biocompatibility. By enhancing drug delivery through blood vessels, SLNs have been used to improve the efficacy of cancer treatments. Breast cancer, the most common malignancy in women, has a declining mortality rate but remains incurable. Recently, as an anticancer drug delivery system, SLNs have been widely used in breast cancer, improving the therapeutic efficacy of drugs. In this review, we discuss the latest advances of SLNs for breast cancer treatment and their potential in clinical use. Full article
(This article belongs to the Special Issue New Insights into Targeted Therapy of Solid Tumors with Polymeric Nanoparticles)
►▼ Show Figures

Figure 1

19 pages, 1031 KiB  
Review
Chronotherapeutics for Solid Tumors
by Claire O. Kisamore, Brittany D. Elliott, A. Courtney DeVries, Randy J. Nelson and William H. Walker II
Pharmaceutics 2023, 15(8), 2023; https://doi.org/10.3390/pharmaceutics15082023 - 26 Jul 2023
Cited by 1 | Viewed by 2020
Abstract
Circadian rhythms are internal manifestations of the 24-h solar day that allow for synchronization of biological and behavioral processes to the external solar day. This precise regulation of physiology and behavior improves adaptive function and survival. Chronotherapy takes advantage of circadian rhythms in [...] Read more.
Circadian rhythms are internal manifestations of the 24-h solar day that allow for synchronization of biological and behavioral processes to the external solar day. This precise regulation of physiology and behavior improves adaptive function and survival. Chronotherapy takes advantage of circadian rhythms in physiological processes to optimize the timing of drug administration to achieve maximal therapeutic efficacy and minimize negative side effects. Chronotherapy for cancer treatment was first demonstrated to be beneficial more than five decades ago and has favorable effects across diverse cancer types. However, implementation of chronotherapy in clinic remains limited. The present review examines the evidence for chronotherapeutic treatment for solid tumors. Specifically, studies examining chrono-chemotherapy, chrono-radiotherapy, and alternative chronotherapeutics (e.g., hormone therapy, TKIs, antiangiogenic therapy, immunotherapy) are discussed. In addition, we propose areas of needed research and identify challenges in the field that remain to be addressed. Full article
(This article belongs to the Special Issue New Insights into Targeted Therapy of Solid Tumors with Polymeric Nanoparticles)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop